Mindray to Acquire 75% Stake in DiaSys
By LabMedica International staff writers Posted on 04 Aug 2023 |
Mindray (Shenzhen, China) has agreed to acquire a 75% equity interest in DiaSys Diagnostic Systems GmbH (Holzheim, Germany) through its Dutch subsidiary for an all-cash preliminary purchase price of approximately EUR 115 million with the final amount to be determined as of closing. The agreement is slated to be finalized later this year, pending regulatory approvals and the granting of regulatory approvals. Upon finalizing the transaction, Mindray will hold a 75% stake in DiaSys and consolidate DiaSys and its subsidiaries. DiaSys's wide range of clinical chemistry systems, manufacturing capabilities for controls and calibrators, and a global network of manufacturing and distribution sites synergize fully complement Mindray's extensive hematology and immunoassays product range, creating a plethora of market opportunities.
Recognized globally, DiaSys has over 30 years of experience in the in-vitro diagnostics (IVD) field with production facilities spread across Europe, APAC, and Latin America. Mindray intends to utilize DiaSys's international team of professionals and global supply platforms to expedite the construction of overseas supply chains, aiming for further expansion into global medium to large volume customer segments and delivering more timely and comprehensive professional services to clients. Moreover, DiaSys's vast experience in clinical chemistry is anticipated to bring synergistic value to Mindray's IVD business. DiaSys’s expertise in developing and producing IVD controls and calibrators will complement Mindray’s IVD product line and enhance its system performance.
“We are very pleased to see this collaboration come to fruition, as Mindray’s and DiaSys’ businesses strongly complement each other,” said Wu Hao, President of Mindray. “Through this acquisition, Mindray will effectively improve its overseas supply chain platform and support the penetration of our IVD business in the medium to large customer segments. We look forward to both parties jointly realizing synergies and creating greater value for our customers.”
“DiaSys with its comprehensive range of products and global manufacturing footprints, and Mindray with its total IVD solutions and worldwide network, are ideal partners for lifting synergies in the IVD field,” added Dr. Günther Gorka, DiaSys’s Founder. “The individual strengths of both partners will support each other and help for a common and sustainable success in all regions of the world.”
Related Links:
Mindray
DiaSys Diagnostic Systems
Latest Industry News
- Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine